AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00505947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: infliximab
Description: infliximab 5 mg/Kg body weight by intravenous infusion
Study NCT00505947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo 5 mg/Kg body weight by intravenous infusion
Study NCT00505947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 5 mg/Kg body weight by intravenous infusion
Study NCT00687791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
Description: Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
Study NCT02104960 — intervention group
Intervention type: OTHER
Intervention: Dermatological clinical examination
Description: Clinical pictures, Dermatoscopy, Elastography, Sebumetry
Study NCT02104960 — intervention group
Intervention type: OTHER
Intervention: Biopsy
Description: Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
Study NCT02104960 — intervention group
Intervention type: OTHER
Intervention: Confocal microscopy in vivo
Description: Examination by confocal microscopy in vivo
Study NCT00998556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
Study NCT00156936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
Study NCT00156936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral naltrexone to Medisorb naltrexone 380 mg
Description: Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
Study NCT04070911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WATER
Description: ORAL WATER
Study NCT03608215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
Study NCT03608215 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
Study NCT00422747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasondipropionate
Description: 2 x 100 ug dd for two months, via aerochamber
Study NCT03593980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: 400ml cranberry juice
Study NCT00172055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT04070911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICE APPLICATION
Description: ICE APPLICATION
Study NCT03063814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP
Description: See arm description
Study NCT03063814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PHY
Description: see arm description
Study NCT05240495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive-behavioural therapy
Description: Internet-based Cognitive-behavioural therapy protocol was based on contemporary CBT techniques adapted for adjustment disorders, and recovery from work training inspired by Hahn et al. \[50\]. The iCBT program consisted of ten modules distributed over ten weeks, with modules lasting 60-120 min per week.
Study NCT05240495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work-focused Cognitive-behavioural therapy
Description: The Work-focused Cognitive-behavioural therapy consisted of the exact generic iCBT-modules included in the first experimental group and of additional work-focused modules adapted for adjustment disorders. The W-iCBT added about 2-3 regular pages compared to the generic iCBT.
Study NCT00202982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 20 mg
Description: glatiramer acetate 20 mg
Study NCT00202982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate 40 mg
Description: glatiramer acetate 40 mg
Study NCT02351466 — intervention group
Intervention type: OTHER
Intervention: Observational
Study NCT03625440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: The Digit span test and PASAT with waterpipe smoking
Description: Cognitive tests at baseline and 30minutes after waterpipe smoking
Study NCT03625440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: The Digit span test and PASAT without waterpipe smoking
Description: The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
Study NCT03643328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
Study NCT03643328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasal swabs
Description: Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
Study NCT03933956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Oral empagliflozin 10mg daily for 30 days
Study NCT01285037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2801653
Description: LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Study NCT01285037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Study NCT01285037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
Study NCT01285037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
Study NCT01285037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
Study NCT04325100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switch - Individual sessions
Description: Participants follow the Switch intervention through individual sessions (1 hour, twice a week, for around 2 months).~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual can be obtained from the main investigator (in French).
Study NCT04325100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switch - Group programme
Description: Participants follow the Switch group programme (2 hours, twice a week, for around 2 months).~During the group sessions, a powerpoint presentation and different media are used to present the different parts of the motivation model. Participants learn the different strategies (e.g., cognitive defusion, pleasure anticipation, problem solving) through individual and group exercises.~Participants are provided with a folder which presents the rational for each strategy. Take-home assignments are given and stored in the same folder. Participants are also given small cards (that can fit in their wallet) containing the key elements of each strategy.~The intervention manual and the presentation material can be obtained from the main investigator (in French).
Study NCT01388270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a pre-heparin-coated hemodialysis filter; Hepran
Description: Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
Study NCT03581422 — intervention group
Intervention type: DRUG
Intervention: hCG administration before embryo transfer
Description: Thawed embryo transfer with ovulation triggered by hCG
Study NCT02770625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISU302
Description: 60 U/kg given intravenously
Study NCT03027830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFR pressure-wire
Description: The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period
Study NCT03027830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Other diagnostic devices (including FFR and angiography)
Study NCT01529060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylbutyrate
Description: Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
Study NCT01529060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
Study NCT01450462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
Study NCT01804738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jasmine rice
Description: Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
Study NCT01987908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
Study NCT01987908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04058587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib
Description: The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).
Study NCT00189462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Study NCT00189462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01262625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCTA
Description: Complete diagnostic CCTA per protocol specifications.
Study NCT01262625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPECT MPI/ICA
Description: Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
Study NCT04075331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab 100mg subcutaneous injection
Study NCT04075331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for subcutaneous injection
Study NCT03089957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: 200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
Study NCT03089957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care in ICU.
Study NCT03089957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care in ICU.
Study NCT01137357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt with L. plantarum strain
Description: Intake of yoghurt during 4 weeks
Study NCT01137357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yoghurt with L.casei
Description: Intake of yoghurt during 4 weeks
Study NCT01137357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt with L. plantarum strain
Description: Yoghurt with L. plantarum strain
Study NCT01137357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt
Description: Intake of yoghurt during 4 weeks
Study NCT01804738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parboiled basmati rice
Description: Standardised rice:cooking liquid for 50g available carbohydrate portion
Study NCT04499313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Injectable solution
Study NCT00378326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
Study NCT01450462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
Study NCT01582126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group balance training
Description: Balance training i group with focus on core stability exercises and dual attention activities.
Study NCT04140188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Senti-Scint (99mTc- pertechnetate combined with human albumin)
Description: Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.
Study NCT03472365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study NCT03472365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
Study NCT03472365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
Study NCT03472365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 375 mg administered as continuous oral once daily (QD) of each 3-week cycle.
Study NCT02688348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02688348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03769844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity \< 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
Study NCT03657329 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dreem
Description: Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
Study NCT00902109 — intervention group
Intervention type: DEVICE
Intervention: Perimetry
Description: different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
Study NCT00902109 — intervention group
Intervention type: DEVICE
Intervention: Confocal Scanning Laser Tomography
Description: HRT examinations for the clinical evaluation of the optic disc.
Study NCT00902109 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: imaging of the retinal nerve fiber layer
Study NCT03025880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.
Study NCT03025880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
Study NCT04259528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric endoscopic ultrasound
Description: endoscopic ultrasound at the esophageal stricture site to assess echo texture and esophageal layers
Study NCT01487369 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
Study NCT02377895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasapaque Nasal Solution
Study NCT02377895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Saline Nasal Solution
Study NCT02648620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurVeil Drug Coated Balloon
Description: Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
Study NCT02648620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty
Description: Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
Study NCT04067102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Description: Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment